{"type":"trials","record":{"id":33564,"source_id":"clinicaltrials-gov","external_id":"NCT06448052","title":"Umbilical Cord Mesenchymal Stem Cell for Aging-related Low-grade Inflammation","brief_summary":"The goal of this single-group, open-label, phase I/II clinical trial is to evaluate the safety and efficacy of the transplantation of umbilical cord mesenchymal stem cells in aging-related low-grade inflammation patients' pro-inflammatory cytokines. The main questions to answer are: * Is the transplantation of umbilical cord mesenchymal stem cells in aging-related low-grade inflammation patients safe? * Comparison of the expression levels of pro-inflammatory cytokines (IL-1α/β, TNF-α/β, IL-6, IL-11, IL-18, IFN-γ) in the patient's blood before (day 0), after 90 days, and after 180 days of cell transplantation. * Comparison of the expression levels of anti-inflammatory cytokines (IL-10, TGFβ, IL-1) in the patient's blood before (day 0), after 90 days, and after 180 days of cell transplantation. * Comparison of the inflammation balance by the ratios of pro-inflammatory cytokines to anti-inflammatory cytokines in the patient's blood before (day 0), after 90 days, and after 180 days of cell transplantation. * Comparison of the HbA1C index in the diabetes patient's blood before (day 0), after 90 days, and after 180 days of cell transplantation. * Comparision of the indices of Cholesterol, Triglyceride, LDLc, HDLc in the dislipidemia patient's blood before (day 0), after 90 days, and after 180 days of cell transplantation. * Comparison of the BMI in the obese patient's blood before (day 0), after 90 days, and after 180 days of cell transplantation. * Determination of adverse effect frequency in the patients before (day 0), during, after 90 days, and after 180 days of cell transplatation. Participants will receive two intravenous infusions of 100 million umbilical cord mesenchymal stem cells on days 0 and 90. The patient will be monitored for safety and measured as per the study protocol until day 180.","overall_status":"Active Not Recruiting","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Nguyen Ton Ngoc Huynh","enrollment":72,"countries":["Vietnam"],"start_date":"2023-11-01","completion_date":"2026-10-30","last_update_date":"2024-06-07","source_url":"https://clinicaltrials.gov/study/NCT06448052","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:20:11.10691+00:00","last_seen_at":"2026-09-25T06:05:37.656+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"40 Years to 64 Years","comparator":null,"organization":"DNA International Hospital","interventions":["umbilical cord mesenchymal stem cell"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Adverse effect — From the patients enrolled in the study until 30 days after the study ended.","Serve adverse effect — From the patients enrolled in the study until 30 days after the study ended.","the expression levels of pro-inflammatory cytokines — Before (day 0), after 90 days, and after 180 days of cell transpl…","the expression levels of anti-inflammatory cytokines — Before (day 0), after 90 days, and after 180 days of cell transp…","the inflammation balance — Before (day 0), after 90 days, and after 180 days of cell transplantation","Effect in diabetes patient — Before (day 0), after 90 days, and after 180 days of cell transplantation","Effect in dislipidemia patient — Before (day 0), after 90 days, and after 180 days of cell transplantation","Effect in obese patient — Before (day 0), after 90 days, and after 180 days of cell transplantation."],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Inflammatory Disease","Aging Problems","Obese","Lipid Metabolism Disorders","Diabetes","umbilical cord mesenchymal stem cell"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: stem cell.","quality_checked_at":"2026-09-25T06:05:39.423355+00:00","duplicate_cluster_key":"id:nct06448052","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-11-01 to 2026-10-30","comparator":null,"confidence":"structured-source","population":"ALL · 40 Years to 64 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:05:37.668Z","intervention":["umbilical cord mesenchymal stem cell"],"participants":72,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Adverse effect — From the patients enrolled in the study until 30 days after the study ended.","Serve adverse effect — From the patients enrolled in the study until 30 days after the study ended.","the expression levels of pro-inflammatory cytokines — Before (day 0), after 90 days, and after 180 days of cell transpl…","the expression levels of anti-inflammatory cytokines — Before (day 0), after 90 days, and after 180 days of cell transp…","the inflammation balance — Before (day 0), after 90 days, and after 180 days of cell transplantation","Effect in diabetes patient — Before (day 0), after 90 days, and after 180 days of cell transplantation","Effect in dislipidemia patient — Before (day 0), after 90 days, and after 180 days of cell transplantation","Effect in obese patient — Before (day 0), after 90 days, and after 180 days of cell transplantation."],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"stem-cells","is_published":true,"match_reasons":["Title contains controlled term: stem cell.","Abstract contains controlled term: stem cell.","Source terminology contains: stem cell.","Title supplies longevity context: aging.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Stem cells","slug":"stem-cells"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/33564","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}